Imatinib Wockhardt Uk (Imatinib Mesilate)

Imatinib mesylate blocks the ATP‑binding sites of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases. By inhibiting these enzymes, it stops downstream signaling that promotes malignant cell proliferation, leading to tumor control or regression.

The dose of Imatinib Wockhardt Uk is individualized by the prescribing physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and other clinical factors. Only a qualified healthcare professional should determine the regimen.

Safety data for imatinib in pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should discuss contraception with their clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Imatinib was the first BCR‑ABL tyrosine kinase inhibitor approved for chronic myeloid leukemia and remains a standard first‑line option. Newer agents such as dasatinib or nilotinib have different potency and side‑effect profiles, but imatinib’s long‑term safety record and extensive clinical experience make it a widely used reference therapy.

Imatinib Wockhardt Uk should be stored at room temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. Do not store in a refrigerator or freezer unless the label specifically indicates otherwise.

The product is taken orally, usually as a whole tablet with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their healthcare provider to maintain consistent drug exposure.

Serious risks include severe neutropenia, hepatotoxicity, cardiac failure, pulmonary hypertension, and rare anaphylactic reactions. Patients should be monitored regularly for blood counts, liver enzymes, cardiac function and any signs of unexpected bleeding or allergic response.

Imatinib is contraindicated in patients with known hypersensitivity to imatinib mesylate or any of the tablet’s excipients. Caution is also advised for individuals with severe hepatic impairment, uncontrolled cardiac disease, or those taking medications that strongly interact with CYP3A4 without appropriate monitoring.